To evaluate the retinal and choroidal vascular structures in patients with anxiety disorders.
Methods
Thirthy-four eyes of 34 patients who were diagnosed with any anxiety disorders were compared with 32 eyes of 32 age- and sex-matched controls. Central macular thickness (CMT), foveal vascular zone (FAZ) area, total retinal vascular densities of superficial and deep capillary plexus (VDSCP, VDDCP), outer retinal and choriocapillary layers (ORL, CCL) blood flow rates, central subfoveal choroidal thickness (SFCT) and choriodal vascularity index (CVI) were evaluated with optical coherence tomography angiography (OCT-A) and enhanced depth imaging optical coherence tomography (EDI-OCT).
Results
No statistical differences were found between the study and control groups in terms of CMT, FAZ area, VDSCP, VDDCP, ORL and CCL blood flow rates. The mean SFCT was 346.26 ± 64.26 µm in patients with anxiety disorder and was found to be statistically significantly thicker than the control group (319.56 ± 37.19 µm) (p = 0.042). Besides, CVI was significantly lower in the study group (71.09 ± 2.64 vs 73.13 ± 3.31, p = 0.008).
Conclusion
In people with anxiety disorders, the SFCT was found to be thicker and CVI was found to be lower than normal subjects. Although anxiety and stress are important factors in central serous chorioretinopathy, multifactorial factors, including ocular factors, play a role in the pathophysiology of the disease. There is a need for prospective studies with larger series on the subject.
ManayathGJRanjanRShahVS, et al.Central serous chorioretinopathy: current update on pathophysiology and multimodal imaging. Oman J Ophthalmol2018; 11: 103–112. doi:https://doi.org/10.4103/ojo.OJO_75_2017
2.
ManayathGJShahVSSaravananVR, et al.Polypoidal choroidal vasculopathy associated with Central Serous chorioretinopathy: pachychoroid Spectrum of Diseases. Retina2018; 38: 1195–1204. doi:https://doi.org/10.1097/IAE.0000000000001665
3.
YangLJonasJBWeiW. Optical coherence tomography-assisted enhanced depth imaging of central serous chorioretinopathy. Invest Ophthalmol Vis Sci2013; 54: 4659–4665. doi:https://doi.org/10.1167/iovs.12-10991
4.
KimY-KWooSJParkKH, et al.Association of central serous chorioretinopathy with psychosocial factors is dependent on its phase and subtype. Korean J Ophthalmol2018; 32: 281–289. https://doi.org/10.3341/kjo.2017.0144
5.
KabediNNKayembeDLMwanzaJC. Vision-related quality of life, anxiety and depression in congolese patients with polypoidal choroidal vasculopathy. Semin Ophthalmol2020; 35: 156–163. doi:https://doi.org/10.1080/08820538.2020.1774623
6.
YannuzziLA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc1986; 84: 799–845.
7.
ChatziralliIKabanarouSAParikakisE, et al.Risk factors for central serous chorioretinopathy: multivariate approach in a case-control study. Curr Eye Res2017; 42: 1069–1073.
8.
JiYLiMZhangX, et al.Poor sleep quality is the risk factor for central serous chorioretinopathy. J Ophthalmol2018; 2018: 9450297.
9.
MatetADaruichAZolaM, et al.Risk factors for recurrences of central serous chorioretinopathy. Retina2018; 38: 1403–1414.
10.
LahousenTPainoldALuxenbergerW, et al.Psychological factors associated with acute and chronic central serous chorioretinopathy. Nord J Psychiatry2016; 70: 24–30. doi:https://doi.org/10.3109/08039488.2015.1041156
11.
van HaalenFMvan DijkEHCAndelaCD, et al.Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. Acta Ophthalmol2019; 97: e572–e579. doi:https://doi.org/10.1111/aos.13952
12.
HaimoviciRKohSGagnonDR, et al.Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology2004; 111: 244–249.
13.
Abu el-AsrarAM. Central serous chorioretinopathy complicating systemic corticosteroid therapy. Eur J Ophthalmol1997; 7: 297–300.
14.
KashaniAHChenCLGahmJK, et al.Optical coherence tomography angiography: a comprehensive review of current methods and clinical applications. Prog Retin Eye Res2017; 60: 66–100. doi:https://doi.org/10.1016/j.preteyeres.2017.07.002
15.
GarritySTA IafeNPhasukkijwatanaN, et al.Quantitative analysis of three distinct retinal capillary plexuses in healthy eyes using optical coherence tomography angiography. Invest Ophthalmol Vis Sci2017; 58: 5548–5555. doi:https://doi.org/10.1167/iovs.17-22036
16.
AyyildizDAyyildizT. Central choroidal thickness in children and adolescents with anxiety disorders: enhanced depth imaging optical coherence tomography findings. Int J Ophthalmol2020; 13: 1580–1585.
17.
KalenderogluAÇelikMSevgi-KaradagA, et al.Optic coherence tomography shows inflammation and degeneration in majör depressive disorder patients correlated with disease severity. J Affect Disord2016; 204: 159–165.
18.
SonodaSSakamotoTYamashitaT, et al.Luminal and stromal areas of choroid determined by binarization method of optical coherence tomographic images. Am J Ophthalmol2015; 159: 1123–1131.e1.
19.
NongremGSurveAVenkateshP, et al.Effect of short-term meditation training in central serous chorioretinopathy. Indian J Ophthalmol2021; 69: 3559–3563.
20.
YannuzziLA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol2010; 149: 361–363.e1.
21.
YoshiokaHKatsumeYAkuneH. Experimental central serous chorioretinopathy in monkey eyes: fluorescein angiographic findings. Ophthalmologica1982; 185: 168–178.
22.
VenkateshPGadiaRTewariHK, et al.Prehypertension may be common in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol2006; 244: 1101–1103.
23.
HaradaTHaradaK. Six cases of central serous choroidopathy induced by systemic corticosteroid therapy. Doc Ophthalmol1985; 60: 37–44.
24.
BouzasEAKaradimasPPournarasCJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol2002; 47: 431–448.
25.
Gungor KobatSYusufogluEGulFC, et al.Plasma dopamine and catecholamine levels in patients with central serous chorioretinopathy. J Fr Ophtalmol2021; 44: 621–625.
26.
SakaueMHoffmanBB. Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest1991; 88: 385–389.
27.
YangSZhangL. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol2004; 2: 1–12.
28.
AgrawalRGuptaPTanKA, et al.Choroidal vascularity index as a measure of vascular status of the choroid: measurements in healthy eyes from a population-based study. Sci Rep2016; 6: 21090.
29.
KongMChoiDYHanG, et al.Measurable range of subfoveal choroidal thickness with conventional spectral domain optical coherence tomography. Transl Vis Sci Technol2018; 7: 16.
30.
IovinoCPellegriniMBernabeiF, et al.Choroidal vascularity index: an in-depth analysis of this novel optical coherence tomography parameter. J Clin Med2020; 9: 595.
31.
AgrawalRChhablaniJTanKA, et al.Choroidal vascularity index in central serous chorioretinopathy. Retina2016; 36: 1646–1651.
32.
YangJWangEYuanM, et al.Three-Dimensional choroidal vascularity index in acute central serous chorioretinopathy using swept-source optical coherence tomography. Graefes Arch Clin Exp Ophthalmol2020; 258: 241–247.
33.
NicholsonBNobleJForooghianF, et al.Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol2013; 58: 103–126.
34.
VermaABacciTSarrafD, et al.Vortex vein imaging: what can it tell us?Clin Ophthalmol2021; 15: 3321–3331.
35.
ZengQLuoLYaoY, et al.Three-dimensional choroidal vascularity index in central serous chorioretinopathy using ultra-widefield swept-source optical coherence tomography angiography. Front Med (Lausanne)2022; 9: 967369.
36.
PangCEShahVPSarrafD, et al.Ultra-widefield imaging with autofluorescence and indocyanine green angiography in central serous chorioretinopathy. Am J Ophthalmol2014; 158: 362–371.e2. doi:https://doi.org/10.1016/j.ajo.2014.04.021
